2009 Influenza A H1N1 °¨¿° Áß ¼Ò¾Æ ÁßÁõ ȯÀÚ¿¡ ´ëÇÑ °í¿ë·® Oseltamivir Åõ¿© È¿°ú
Effectiveness of double-dose oseltamivir for pediatric patients with severe 2009 pandemic influenza A H1N1

Allergy Asthma & Respiratory Disease 2014³â 2±Ç 1È£ p.64 ~ p.69

Á¶Çö¼®(Cho Hyun-Seok) - °­¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¼Ò¾Æ°úÇб³½Ç
¾çÁ¤Èñ(Yang Jeong-Hee) - °­¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø °¡Á¤ÀÇÇб³½Ç
ÀÌÁØÈ£(Lee Joon-Ho) - °­¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¼Ò¾Æ°úÇб³½Ç
¾È¼º¿¬(Ahn Sung-Yeon) - °­¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¼Ò¾Æ°úÇб³½Ç
ÀÌÇö¼ö(Lee Hyeon-Soo) - °­¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¼Ò¾Æ°úÇб³½Ç
±èÀÚ°æ(Kim Ja-Kyoung) - °­¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¼Ò¾Æ°úÇб³½Ç
¹Î¼¼¶ó(Min Se-Ra) - °­¿ø´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¼Ò¾Æ°úÇб³½Ç

Abstract

Purpose: We aimed to evaluate the use and safety of double dose oseltamivir for patients manifesting severe respiratory symptoms or showing no improvement of clinical symptoms after 72 hours¡¯ treatment with the usual oseltamivir dosage.

Methods: We analyzed the clinical features of 2009 influenza A H1N1 inpatients who had been admitted to a university hospital¡¯s Department of Pediatrics between August 2009 and January 2010. The Influenza A H1N1 diagnoses were confirmed by real-time reverse transcriptase polymerase chain reaction.

Results: The study participants numbered 157 (mean age, 5.0 years; male-to-female ratio, 1.1:1). Among them, twenty (mean age, 5.2 years) were administered double dose oseltamivir. This double dose group showed higher peak body temperatures and more abnormal radiologic results than the other, usual-dose group. The mean time duration between high fever and afebrile status after initiation of double-dose oseltamivir administration was 2.1 days, whereas that within the usual-dose group was 1.7 days. There were no adverse effects in the patients treated with double-dose oseltamivir.

Conclusion: Double-dose oseltamivir was well tolerated in patients with severe 2009 influenza A H1N1 infection.

Ű¿öµå

Influenza A virus, H1N1 subtype, Pediatrics, Severity of illness index, Oseltamivir
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå